RS50233B - Stabilne farmaceutske formulacije rastvora za inhalatore odmerene doze pod pritiskom - Google Patents
Stabilne farmaceutske formulacije rastvora za inhalatore odmerene doze pod pritiskomInfo
- Publication number
- RS50233B RS50233B YU87902A YUP87902A RS50233B RS 50233 B RS50233 B RS 50233B YU 87902 A YU87902 A YU 87902A YU P87902 A YUP87902 A YU P87902A RS 50233 B RS50233 B RS 50233B
- Authority
- RS
- Serbia
- Prior art keywords
- metered dose
- dose inhalers
- stable pharmaceutical
- pharmaceutical solution
- solution formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Aerosolni preparat naznačen time što sadrži ß2 agonist iz grupe fenilalkiloamina koji nosi funkcionalnu grupu osetljivu na oksidativne i/ili hidrolitičke reakcije u rastvoru vodenog HFA poti-skivača, ko-rastvarač odabran od farmaceutski prihvatljivih alkohola, gde je pH rastvora podesen do izmedu 2.5 i 5.0 dodavanjem malih količina mineralne kiseline kao što su hlorovodonična, azotna i fosforna kiselina, pri čemu je aktivni sastojak (ß2 -antagonist odabran od formoterola i TA-2005, njihovih soli ili njihovih kombinacija sa steroidima, kao što su beklometazon dipropionat, flutikazon propionat, budesonid i njegov 22R-epimer. Prijava sadrži 7 zavisnih patentnih zahteva.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
YU87902A RS50233B (sr) | 2000-05-22 | 2000-05-22 | Stabilne farmaceutske formulacije rastvora za inhalatore odmerene doze pod pritiskom |
MEP-321/08A MEP32108A (en) | 2000-05-22 | 2005-05-22 | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
YU87902A RS50233B (sr) | 2000-05-22 | 2000-05-22 | Stabilne farmaceutske formulacije rastvora za inhalatore odmerene doze pod pritiskom |
Publications (2)
Publication Number | Publication Date |
---|---|
YU87902A YU87902A (sh) | 2005-06-10 |
RS50233B true RS50233B (sr) | 2009-07-15 |
Family
ID=47739648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU87902A RS50233B (sr) | 2000-05-22 | 2000-05-22 | Stabilne farmaceutske formulacije rastvora za inhalatore odmerene doze pod pritiskom |
Country Status (1)
Country | Link |
---|---|
RS (1) | RS50233B (sr) |
-
2000
- 2000-05-22 RS YU87902A patent/RS50233B/sr unknown
Also Published As
Publication number | Publication date |
---|---|
YU87902A (sh) | 2005-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MEP32108A (en) | Stable pharmaceutical solution formulations for pressurised metered dose inhalers | |
CY1122851T1 (el) | Υπερλεπτο σκευασμα φορμοτερολης | |
RS52940B (sr) | Farmaceutske formulacije rastvora za izmerene doze inhalatora pod pritiskom | |
ATE308317T1 (de) | Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung | |
ES2188092T3 (es) | Composicion de aerosol. | |
IT1303788B1 (it) | Formulazioni di aerosol medicinali. | |
RS51274B (sr) | Farmaceutski aerosolni preparat | |
YU64804A (sh) | Inhalator odmerene doze | |
DK0656206T3 (da) | Aerosolformuleringer uden chlorfluorcarbonforbindelser | |
ECSP088653A (es) | Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva | |
DK1303258T3 (da) | Hidtil ukendte aerosolformuleringer, der indeholder et polært, floureret molekyle | |
IT1317720B1 (it) | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. | |
PE20011271A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
TNSN07289A1 (en) | Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent | |
CL2012000947A1 (es) | Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis. | |
NO20083759L (no) | Doserings aerosoler for administrering av farmasoytiske preparater | |
AR008309A1 (es) | Formulaciones de aerosol en suspensión de furoato de mometasona , usos de de las mismas e inhalador de dosis de medida | |
RS50233B (sr) | Stabilne farmaceutske formulacije rastvora za inhalatore odmerene doze pod pritiskom | |
CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion |